Literature DB >> 15066236

What's new in the field of prostate cancer chemoprevention?

Kanwaljit Mahal1, Javier Hernandez, Joseph W Basler, Ian M Thompson.   

Abstract

Chemoprevention trials for several malignancies are completed, planned, or underway. Prostate cancer is one of the most common forms of cancer and understandably has received considerable recent attention as a potential target for chemoprevention. This article examines chemoprevention trials for prostate cancer, including the Prostate Cancer Prevention Trial, Selenium and Vitamin E Cancer Prevention Trial, and cyclooxygenase inhibitors in the prevention of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15066236     DOI： 10.1007/s11912-004-0055-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  49 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

2.  Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates.

Authors:  R E Tarone; K C Chu; O W Brawley
Journal:  Epidemiology       Date:  2000-03       Impact factor: 4.822

3.  Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.

Authors:  T Kamijo; T Sato; Y Nagatomi; T Kitamura
Journal:  Int J Urol       Date:  2001-07       Impact factor: 3.369

4.  Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells.

Authors:  Cheng Jiang; Zaisen Wang; Howard Ganther; Junxuan Lü
Journal:  Mol Cancer Ther       Date:  2002-10       Impact factor: 6.261

5.  Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer.

Authors:  K Yoshizawa; W C Willett; S J Morris; M J Stampfer; D Spiegelman; E B Rimm; E Giovannucci
Journal:  J Natl Cancer Inst       Date:  1998-08-19       Impact factor: 13.506

6.  Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency.

Authors:  J Imperato-McGinley; T Gautier; K Zirinsky; T Hom; O Palomo; E Stein; E D Vaughan; J A Markisz; E Ramirez de Arellano; E Kazam
Journal:  J Clin Endocrinol Metab       Date:  1992-10       Impact factor: 5.958

7.  Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines.

Authors:  Vasundara Venkateswaran; Neil E Fleshner; Laurence H Klotz
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

8.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

9.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

Review 10.  Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.

Authors:  Suphat Subongkot; David Frame; William Leslie; Deborah Drajer
Journal:  Pharmacotherapy       Date:  2003-01       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.